Coeptis Therapeutics (NASDAQ:ZSQR) Issues Quarterly Earnings Results

Key Points

• Coeptis Therapeutics reported a quarterly loss of $0.28 per share, alongside a negative return on equity of 92.29% and a negative net margin of 810.04%.
• Shares rose $0.27 to $4.16, but remained well below the 50-day and 200-day moving averages and near the company’s 12-month low of $3.77.
• Wall Street Zen downgraded the stock from “hold” to “sell,” leaving Coeptis with an overall “Sell” rating from the one analyst tracked by MarketBeat; institutional investors owned 13.88% of the company.

Coeptis Therapeutics (NASDAQ:ZSQR - Get Free Report) issued its earnings results on Thursday. The company reported ($0.28) earnings per share for the quarter, Zacks reports. Coeptis Therapeutics had a negative return on equity of 92.29% and a negative net margin of 810.04%.

Coeptis Therapeutics Stock Performance

Shares of Coeptis Therapeutics stock traded up $0.27 on Thursday, reaching $4.16. 398,778 shares of the stock were exchanged, compared to its average volume of 260,849. The company has a quick ratio of 3.25, a current ratio of 3.25 and a debt-to-equity ratio of 0.01. Coeptis Therapeutics has a twelve month low of $3.77 and a twelve month high of $21.41. The firm has a market capitalization of $213.95 million, a price-to-earnings ratio of -1.65 and a beta of -0.20. The business has a 50 day moving average price of $8.56 and a two-hundred day moving average price of $10.86.

Analyst Ratings Changes

Separately, Wall Street Zen downgraded Coeptis Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, June 13th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of "Sell".

Hedge Funds Weigh In On Coeptis Therapeutics

A number of institutional investors have recently bought and sold shares of ZSQR. State Street Corp boosted its holdings in shares of Coeptis Therapeutics by 35.0% in the 4th quarter. State Street Corp now owns 26,830 shares of the company's stock valued at $382,000 after acquiring an additional 6,962 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Coeptis Therapeutics by 12.6% during the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company's stock worth $600,000 after purchasing an additional 4,721 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Coeptis Therapeutics during the fourth quarter worth $259,000. Finally, Steward Partners Investment Advisory LLC lifted its position in Coeptis Therapeutics by 100.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company's stock valued at $71,000 after purchasing an additional 2,500 shares during the period. 13.88% of the stock is owned by hedge funds and other institutional investors.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source